Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50%

by Gainor, J. F., Rizvi, H., Aguilar, E. Jimenez, Skoulidis, F., Yeap, B. Y., Naidoo, J., Khosrowjerdi, S., Mooradian, M., Lydon, C., Illei, P., Zhang, J., Peterson, R., Ricciuti, B., Nishino, M., Zhang, J., Roth, J. A., Grishman, J., Anderson, D., Little, B. P., Carter, B. W., Arbour, K., Sauter, J. L., Mino-Kenudson, M., Heymach, J. V., Digumarthy, S., Shaw, A. T., Awad, M. M., Hellmann, M. D.
Published in Ann Oncol (2019)

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer

by Hastings, K, Yu, H A, Wei, W, Sanchez-Vega, F, DeVeaux, M, Choi, J, Rizvi, H, Lisberg, A, Truini, A, Lydon, C A, Liu, Z, Henick, B S, Wurtz, A, Cai, G, Plodkowski, A J, Long, N M, Halpenny, D F, Killam, J, Oliva, I, Schultz, N, Riely, G J, Arcila, M E, Ladanyi, M, Zelterman, D, Herbst, R S, Goldberg, S B, Awad, M M, Garon, E B, Gettinger, S, Hellmann, M D, Politi, K
Published in Ann Oncol (2019)